Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
Mark Sausen(Human Genome Sciences (United States)), Victor E. Velculescu(Johns Hopkins University), David S. Klimstra(Memorial Sloan Kettering Cancer Center), Rebecca Leary(Novartis Foundation), Peter J. O’Dwyer(University of Pennsylvania), Anirban Maitra(The University of Texas Southwestern Medical Center), James R. White(University of Maryland, College Park), Luis A. Díaz(Memorial Sloan Kettering Cancer Center), Rob Scharpf(Johns Hopkins University), Craig B. Thompson(Memorial Sloan Kettering Cancer Center), Valsamo Anagnostou(Bloomberg (United States)), James R. Eshleman(Johns Hopkins Medicine), Carolyn Hruban(Johns Hopkins University), Julia S. Johansen(Hvidovre Hospital), Derek Murphy(Human Genome Sciences (United States)), David C. Linehan(Washington University in St. Louis), Vilmos Adleff(Johns Hopkins University), Jillian Phallen(Johns Hopkins University), Jeffrey A. Drebin(University of Pennsylvania), Michael T. Barrett(Translational Genomics Research Institute), Daniel D. Von Hoff, Qing Kay Li(Johns Hopkins University), Sonya Parpart-Li(Human Genome Sciences (United States)), Siân Jones(Human Genome Sciences (United States)), Peter J. Allen(Memorial Sloan Kettering Cancer Center), Ralph H. Hruban(Johns Hopkins University)
Cited by 484
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cancer Genome Landscapes
|Science|2013|8k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k